Headlands Technologies LLC grew its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) by 377.0% in the second quarter, HoldingsChannel.com reports. The firm owned 29,194 shares of the biopharmaceutical company’s stock after acquiring an additional 23,074 shares during the period. Headlands Technologies LLC’s holdings in Xenon Pharmaceuticals were worth $1,762,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently modified their holdings of XENE. Danske Bank A S purchased a new position in shares of Xenon Pharmaceuticals during the 3rd quarter valued at $32,000. Kestra Advisory Services LLC bought a new stake in Xenon Pharmaceuticals during the fourth quarter valued at about $33,000. Osaic Holdings Inc. lifted its position in shares of Xenon Pharmaceuticals by 541.4% in the second quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 1,034 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in shares of Xenon Pharmaceuticals in the fourth quarter valued at about $43,000. Finally, Rockefeller Capital Management L.P. boosted its stake in shares of Xenon Pharmaceuticals by 450.0% in the fourth quarter. Rockefeller Capital Management L.P. now owns 1,100 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 900 shares during the period. 95.45% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
XENE has been the subject of several research analyst reports. Royal Bank Of Canada cut their target price on Xenon Pharmaceuticals from $82.00 to $81.00 and set an “outperform” rating for the company in a research report on Friday, August 7th. Wall Street Zen upgraded Xenon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a report on Monday, July 6th. Wells Fargo & Company reiterated an “overweight” rating and set a $69.00 price objective on shares of Xenon Pharmaceuticals in a research report on Sunday, May 10th. Finally, Needham & Company LLC dropped their target price on shares of Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating for the company in a research report on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $77.13.
Insiders Place Their Bets
In other news, Director Gillian Cannon sold 1,190 shares of the stock in a transaction on Friday, June 5th. The shares were sold at an average price of $53.14, for a total value of $63,236.60. Following the sale, the director owned 1,455 shares of the company’s stock, valued at approximately $77,318.70. This represents a 44.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Gary Patou sold 1,322 shares of the firm’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $53.14, for a total transaction of $70,251.08. Following the completion of the sale, the director owned 24,896 shares of the company’s stock, valued at $1,322,973.44. This trade represents a 5.04% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 12,512 shares of company stock valued at $774,088 over the last three months. 2.91% of the stock is owned by company insiders.
Xenon Pharmaceuticals Stock Performance
XENE stock opened at $60.22 on Tuesday. The firm has a fifty day moving average price of $63.29 and a 200 day moving average price of $56.61. Xenon Pharmaceuticals Inc. has a fifty-two week low of $35.60 and a fifty-two week high of $72.66. The firm has a market cap of $5.82 billion, a PE ratio of -12.70 and a beta of 0.62.
Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.16) by $0.05. During the same quarter in the previous year, the firm earned ($1.07) EPS. On average, equities analysts predict that Xenon Pharmaceuticals Inc. will post -4.73 EPS for the current year.
Xenon Pharmaceuticals Company Profile
Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.
The company’s pipeline comprises multiple preclinical and clinical programs.
Featured Stories
- Five stocks we like better than Xenon Pharmaceuticals
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Want to see what other hedge funds are holding XENE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report).
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
